Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.770
-0.050 (-1.31%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cytek Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 200.45 | 193.02 | 164.04 | 127.95 | 92.84 | Upgrade
|
| Revenue Growth (YoY) | 3.85% | 17.67% | 28.20% | 37.82% | 60.39% | Upgrade
|
| Cost of Revenue | 89.35 | 83.59 | 63.06 | 48.81 | 41.13 | Upgrade
|
| Gross Profit | 111.11 | 109.43 | 100.97 | 79.14 | 51.71 | Upgrade
|
| Selling, General & Admin | 94.83 | 93.12 | 67.92 | 45.55 | 24.36 | Upgrade
|
| Research & Development | 39.4 | 44.15 | 34.86 | 24.44 | 13.69 | Upgrade
|
| Operating Expenses | 134.23 | 137.27 | 102.78 | 69.99 | 38.05 | Upgrade
|
| Operating Income | -23.12 | -27.85 | -1.8 | 9.16 | 13.66 | Upgrade
|
| Interest Expense | - | -2.07 | -2.57 | -1.74 | -0.33 | Upgrade
|
| Interest & Investment Income | 10.36 | 6.41 | 4.62 | 0.05 | 0.11 | Upgrade
|
| Earnings From Equity Investments | - | - | 0.04 | 0.04 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 4.46 | 7.79 | 0.98 | -1.57 | 0.99 | Upgrade
|
| EBT Excluding Unusual Items | -8.3 | -15.71 | 1.26 | 5.94 | 14.43 | Upgrade
|
| Other Unusual Items | 2.6 | - | - | - | - | Upgrade
|
| Pretax Income | -5.7 | -15.71 | 1.26 | 5.94 | 14.43 | Upgrade
|
| Income Tax Expense | 0.32 | -3.56 | -1.22 | 2.91 | -4.98 | Upgrade
|
| Earnings From Continuing Operations | -6.02 | -12.15 | 2.48 | 3.03 | 19.41 | Upgrade
|
| Minority Interest in Earnings | - | - | 0.09 | 0.03 | - | Upgrade
|
| Net Income | -6.02 | -12.15 | 2.58 | 3.05 | 19.41 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 3 | 16.2 | Upgrade
|
| Net Income to Common | -6.02 | -12.15 | 2.58 | 0.05 | 3.22 | Upgrade
|
| Net Income Growth | - | - | -15.62% | -84.27% | - | Upgrade
|
| Shares Outstanding (Basic) | 131 | 135 | 135 | 77 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 131 | 135 | 139 | 82 | 33 | Upgrade
|
| Shares Change (YoY) | -3.45% | -2.37% | 69.93% | 150.13% | 16.71% | Upgrade
|
| EPS (Basic) | -0.05 | -0.09 | 0.02 | 0.00 | 0.11 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.09 | 0.02 | 0.00 | 0.10 | Upgrade
|
| EPS Growth | - | - | 2906.28% | -99.36% | - | Upgrade
|
| Free Cash Flow | 21.85 | 0.63 | -21.98 | 0.27 | 13.61 | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.01 | -0.16 | 0.00 | 0.42 | Upgrade
|
| Gross Margin | 55.43% | 56.69% | 61.56% | 61.86% | 55.70% | Upgrade
|
| Operating Margin | -11.54% | -14.43% | -1.10% | 7.16% | 14.71% | Upgrade
|
| Profit Margin | -3.00% | -6.29% | 1.57% | 0.04% | 3.46% | Upgrade
|
| Free Cash Flow Margin | 10.90% | 0.33% | -13.40% | 0.21% | 14.66% | Upgrade
|
| EBITDA | -15.91 | -21.8 | 0.69 | 10.4 | 14.26 | Upgrade
|
| EBITDA Margin | -7.94% | -11.29% | 0.42% | 8.13% | 15.36% | Upgrade
|
| D&A For EBITDA | 7.21 | 6.05 | 2.49 | 1.24 | 0.6 | Upgrade
|
| EBIT | -23.12 | -27.85 | -1.8 | 9.16 | 13.66 | Upgrade
|
| EBIT Margin | -11.54% | -14.43% | -1.10% | 7.16% | 14.71% | Upgrade
|
| Effective Tax Rate | - | - | - | 49.02% | - | Upgrade
|
| Revenue as Reported | 200.45 | 193.02 | 164.04 | 127.95 | 92.84 | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.